IndustryCompany release

Scinai nine-month revenue up 167% to $2.8M as CDMO business expands

Scinai Immunotherapeutics Ltd. (SCNI) · Mon 09 Nov 2026

The Israeli biotech's Yavne CDMO operations and an expanded U.S. customer deal drove sales growth, but a one-off accounting gain masks a wider operating loss.

Scinai Immunotherapeutics reported unaudited results for the nine months ended 30 September 2026 on 5 November. Revenue rose 167% to $2.8M, which the company attributes to growth in its contract development and manufacturing (CDMO) activities.

The Yavne CDMO operations, which Scinai acquired in February, contributed to the increase. The company also announced an expanded agreement with a U.S. customer that carries about $5.1M in committed base fees.

The headline net loss narrowed to $0.39M. That improvement came from a $6.4M noncash bargain purchase gain. Such a gain is an accounting item that arises when an acquisition is valued at less than the fair value of the net assets acquired, so it does not reflect trading performance.

Underlying results were weaker. Operating loss widened over the period, and the company recorded a gross loss of $2.97M.

What it means for your team

  • Sponsors weighing CDMO partners should note that Scinai's Yavne site is a recent acquisition (February 2026) and that the segment is still loss-making at gross level.
  • The $5.1M in committed base fees under the expanded U.S. agreement points to some contracted demand, but the summary gives no detail on duration or scope.
  • The narrower net loss comes from a noncash gain, so readers assessing supplier stability should look at the widened operating loss and the $2.97M gross loss.

Company's press release (SEC filing): Scinai Immunotherapeutics Ltd. ↗

Article written by VigiEye from the official source (Scinai Immunotherapeutics Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →